{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T17:08:16Z","timestamp":1774112896803,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00125-025-06637-7","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T20:29:59Z","timestamp":1766176199000},"page":"1216-1225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8173-8255","authenticated-orcid":false,"given":"Jo\u00e3o S\u00e9rgio","family":"Neves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Rita","family":"Leite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Vale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Vasques-N\u00f3voa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelino","family":"Leite-Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"11","key":"6637_CR1","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","volume":"59","author":"P G\u00e6de","year":"2016","unstructured":"G\u00e6de P, Oellgaard J, Carstensen B et al (2016) Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 59(11):2298\u20132307. https:\/\/doi.org\/10.1007\/s00125-016-4065-6","journal-title":"Diabetologia"},{"issue":"6","key":"6637_CR2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/nejmoa0706245","volume":"358","author":"P G\u00e6de","year":"2008","unstructured":"G\u00e6de P, Lund-Andersen H, Parving H-H, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358(6):580\u2013591. https:\/\/doi.org\/10.1056\/nejmoa0706245","journal-title":"N Engl J Med"},{"issue":"5","key":"6637_CR3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2337\/dc15-2439","volume":"39","author":"ND Wong","year":"2016","unstructured":"Wong ND, Zhao Y, Patel R et al (2016) Cardiovascular risk factor targets and cardiovascular disease event risk in diabetes: a pooling project of the atherosclerosis risk in communities study, multi-ethnic study of atherosclerosis, and jackson heart study. Diabetes Care 39(5):668\u2013676. https:\/\/doi.org\/10.2337\/dc15-2439","journal-title":"Diabetes Care"},{"issue":"5","key":"6637_CR4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/dom.13625","volume":"21","author":"W Fan","year":"2019","unstructured":"Fan W, Song Y, Inzucchi SE et al (2019) Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry. Diabetes Obes Metab 21(5):1121\u20131127. https:\/\/doi.org\/10.1111\/dom.13625","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"6637_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41569-023-00877-z","volume":"20","author":"ND Wong","year":"2023","unstructured":"Wong ND, Sattar N (2023) Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol 20(10):685\u2013695. https:\/\/doi.org\/10.1038\/s41569-023-00877-z","journal-title":"Nat Rev Cardiol"},{"issue":"Supplement_1","key":"6637_CR6","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care 48(Supplement_1):S181-s206. https:\/\/doi.org\/10.2337\/dc25-S009","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"6637_CR7","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 10. Cardiovascular disease and risk management: standards of care in diabetes-2025. Diabetes Care 48(Supplement_1):S207-s238. https:\/\/doi.org\/10.2337\/dc25-S010","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"6637_CR8","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 11. Chronic kidney disease and risk management: standards of care in diabetes-2025. Diabetes Care 48(Supplement_1):S239-s251. https:\/\/doi.org\/10.2337\/dc25-S011","journal-title":"Diabetes Care"},{"issue":"4","key":"6637_CR9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27(4):740\u2013756. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"issue":"6","key":"6637_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385(6):503\u2013515. https:\/\/doi.org\/10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"issue":"39","key":"6637_CR11","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44(39):4043\u20134140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"key":"6637_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2024.05.033","volume":"126","author":"R Kreutz","year":"2024","unstructured":"Kreutz R, Brunstr\u00f6m M, Burnier M et al (2024) 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med 126:1\u201315. https:\/\/doi.org\/10.1016\/j.ejim.2024.05.033","journal-title":"Eur J Intern Med"},{"key":"6637_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.05.007","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ et al (2025) 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2025.05.007","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"6637_CR14","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM et al (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227\u20133337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484","journal-title":"Eur Heart J"},{"key":"6637_CR15","unstructured":"World Health Association (2008) Waist circumference and waist-hip ratio. Report of a WHO Expert Consultation Geneva: World Health Organization 2008:8\u201311"},{"issue":"9491","key":"6637_CR16","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/s0140-6736(05)67402-8","volume":"366","author":"KG Alberti","year":"2005","unstructured":"Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome\u2013a new worldwide definition. Lancet 366(9491):1059\u20131062. https:\/\/doi.org\/10.1016\/s0140-6736(05)67402-8","journal-title":"Lancet"},{"issue":"6","key":"6637_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1017\/s0007114519003301","volume":"123","author":"S Gibson","year":"2020","unstructured":"Gibson S, Ashwell M (2020) A simple cut-off for waist-to-height ratio (0\u00b75) can act as an indicator for cardiometabolic risk: recent data from adults in the Health Survey for England. Br J Nutr 123(6):681\u2013690. https:\/\/doi.org\/10.1017\/s0007114519003301","journal-title":"Br J Nutr"},{"issue":"4s","key":"6637_CR18","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"KDIGO CKD Work Group","year":"2024","unstructured":"KDIGO CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4s):S117-s314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"issue":"5","key":"6637_CR19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2337\/dc22-1710","volume":"46","author":"T Heise","year":"2023","unstructured":"Heise T, DeVries JH, Urva S et al (2023) Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care 46(5):998\u20131004. https:\/\/doi.org\/10.2337\/dc22-1710","journal-title":"Diabetes Care"},{"issue":"4","key":"6637_CR20","doi-asserted-by":"publisher","first-page":"E528","DOI":"10.1152\/ajpendo.00330.2023","volume":"326","author":"T Borner","year":"2024","unstructured":"Borner T, De Jonghe BC, Hayes MR (2024) The antiemetic actions of GIP receptor agonism. Am J Physiol Endocrinol Metab 326(4):E528-e536. https:\/\/doi.org\/10.1152\/ajpendo.00330.2023","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"6637_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","volume":"19","author":"R Hammoud","year":"2023","unstructured":"Hammoud R, Drucker DJ (2023) Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol 19(4):201\u2013216. https:\/\/doi.org\/10.1038\/s41574-022-00783-3","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"6637_CR22","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","volume":"36","author":"A Regmi","year":"2024","unstructured":"Regmi A, Aihara E, Christe ME et al (2024) Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metab 36(7):1534-1549.e1537. https:\/\/doi.org\/10.1016\/j.cmet.2024.05.010","journal-title":"Cell Metab"},{"key":"6637_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","volume":"267","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls SJ, Bhatt DL, Buse JB et al (2024) Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J 267:1\u201311. https:\/\/doi.org\/10.1016\/j.ahj.2023.09.007","journal-title":"Am Heart J"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06637-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06637-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06637-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T16:46:04Z","timestamp":1774111564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06637-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["6637"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06637-7","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This publication is based on research using data from data contributors Eli Lilly that have been made available through Vivli. Vivli has not contributed to or approved, and Vivli and Eli Lilly are not in any way responsible for, the contents of this publication. An abstract reporting part of the results presented here was submitted to the Endocrine Society\u2019s annual meeting ENDO 2025 (12 July 2025 to 15 July 2025, San Francisco, CA, USA).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"Data for this post hoc analysis was accessed through the Vivli (Center for Global Clinical Research Data) platform (\n                      \n                      ) with the Vivli ID 00009964.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JSN reports having received consulting and speaker fees from AstraZeneca, BIAL, Boehringer Ingelheim, Eli Lilly and Novo Nordisk and speaker fees from Merck. ARL reports having received consulting fees from BIAL. PM received salary support from an educational grant by Janssen. FVN has received consultancy fees and\/or research support from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Novartis and Ultragenyx. ALM has received research support from Boehringer Ingelheim, AstraZeneca, Novartis. JPF has received research support from Boehringer Ingelheim, AstraZeneca, Novartis, Bial, Salamandra and Bayer. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"JSN, ARL and JPF conceived and designed the study. JSN and ARL performed the data analysis. CV, PM, FVN, ALM and JPF provided methodological and statistical guidance. All authors contributed to the interpretation of the data. JSN and ARL drafted the first version of the manuscript. All authors critically revised the manuscript for important intellectual content and approved the final version to be submitted. JSN and ARL are the guarantors of this work and, as such, had full access to all the data in the analysis and take responsibility for the integrity of the data and the accuracy of the data analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}